Diazoxide
Diazoxide is a medicine that stops insulin-producing tumours releasing insulin. It is used to control dangerous low blood sugar from an insulinoma while the patient is prepared for surgery or when the tumour cannot be removed.
Overview
Diazoxide is a non-diuretic benzothiadiazine that inhibits insulin secretion by opening potassium channels in beta cells; it is licensed as an oral suspension for hypoglycaemia due to hyperinsulinism, including insulinoma and islet cell hyperplasia. Taken two or three times daily, it raises blood glucose within hours and is the first-line medical treatment for insulinoma symptoms before surgery or when surgery is not possible.
Fluid retention, hirsutism and nausea limit its use, and a thiazide diuretic is often added. Everolimus is the alternative when diazoxide fails, because mTOR inhibition also suppresses insulin release in malignant insulinoma. The pancreatic neuroendocrine tumour page names it for controlling hypoglycaemia before insulinoma surgery.
Opens ATP-sensitive potassium channels in pancreatic beta cells and insulinoma cells, preventing the depolarisation that triggers insulin release, so blood glucose rises.
1.Diazoxide acts on its target, the hormone receptor or the enzyme that makes the hormone.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Diazoxide" OR ABSTRACT:"Diazoxide" OR TITLE:"Proglycem" OR ABSTRACT:"Proglycem" OR TITLE:"Diazoxide oral suspension" OR ABSTRACT:"Diazoxide oral suspension") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Diazoxide, not a curated reading list.
Similar pages
not linked directly; found by shared links- Key paperRADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours
- TreatmentPasireotide
Shares Everolimus and the tag subtype-drugs-wave.
- TrialRADIANT-3 and RADIANT-4
- TrialLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
- TrialCOMPETE
- TargetmTOR